Antifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value Growth
出 版 商：GBI Research
出版日期：2012/01/06
頁 數：133頁
文件格式：PDF
價 格：
USD 3,500 (Single-User License)
USD 7,000 (Multi-User License)
USD 10,500 (Global-User License)
USD 7,000 (Multi-User License)
USD 10,500 (Global-User License)
Antifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value Growth
Summary
GBI Research, the leading business intelligence provider has released its latest research “Antifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value Growth”, which provides an insight into antifungals sales and price forecasts until 2017. The report examines the global antifungal therapies, treatment usage patterns and treatment flow algorithm. In addition, the geographical distribution of antifungal therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the Research and Development (R&D) pipeline and the potential future blockbusters until 2017 with in-depth analysis of the top three antifungal therapeutic indications, namely aspergillosis, dermatophytosis and candidiasis. Furthermore, it also includes the market forecasts and treatment usage patterns of these three therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&A) and licensing agreements involving antifungals therapies is also presented.
In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by the GBI Research team of experts.
GBI Research analysis shows that the global antifungals market was estimated at $9.4 billion in 2010, with a Compound Annual Growth Rate (CAGR) of 2.9% during 2002 and 2010. The antifungals market is dominated by generics. GBI Research forecasts that the market will grow at a CAGR of 1.9% during 2010-2017 to $10.8 billion. The patent expiry of a number of major drugs has paved way for the entry of generics.
GBI Research analysis shows that the R&D pipeline for the antifungals market is not strong as it has become a generic market. Currently, only 38 molecules are in R&D, which indicates that antifungals R&D activity will not be very active for at least the next seven to eight years.
Scope
- Data and analysis on the antifungals market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the antifungals market from 2002-2010 with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- The competitive landscape of the global antifungals market including top companies’ benchmarking.
- Key M&A activities and licensing agreements that took place in 2009, 2010 and 2011 in the antifungals market.
Reasons to buy
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce safer and more efficacious first-in-class molecules.
Summary
GBI Research, the leading business intelligence provider has released its latest research “Antifungals Market to 2017 - Generic Erosion of Major Polyenes, Azoles, Allylamines and Echinocandins to Slow Value Growth”, which provides an insight into antifungals sales and price forecasts until 2017. The report examines the global antifungal therapies, treatment usage patterns and treatment flow algorithm. In addition, the geographical distribution of antifungal therapies across the US, the top five countries in the European region and Japan are also provided in the report. The report also includes insights into the Research and Development (R&D) pipeline and the potential future blockbusters until 2017 with in-depth analysis of the top three antifungal therapeutic indications, namely aspergillosis, dermatophytosis and candidiasis. Furthermore, it also includes the market forecasts and treatment usage patterns of these three therapeutic indications. The report also explores the competitive landscape including top companies benchmarking. Finally, the key trend analysis on Mergers and Acquisitions (M&A) and licensing agreements involving antifungals therapies is also presented.
In-depth analysis of the report is based on propriety databases, primary and secondary research and in-house analysis by the GBI Research team of experts.
GBI Research analysis shows that the global antifungals market was estimated at $9.4 billion in 2010, with a Compound Annual Growth Rate (CAGR) of 2.9% during 2002 and 2010. The antifungals market is dominated by generics. GBI Research forecasts that the market will grow at a CAGR of 1.9% during 2010-2017 to $10.8 billion. The patent expiry of a number of major drugs has paved way for the entry of generics.
GBI Research analysis shows that the R&D pipeline for the antifungals market is not strong as it has become a generic market. Currently, only 38 molecules are in R&D, which indicates that antifungals R&D activity will not be very active for at least the next seven to eight years.
Scope
- Data and analysis on the antifungals market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
- Annualized market data for the antifungals market from 2002-2010 with forecasts to 2017.
- Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
- The competitive landscape of the global antifungals market including top companies’ benchmarking.
- Key M&A activities and licensing agreements that took place in 2009, 2010 and 2011 in the antifungals market.
Reasons to buy
- Build effective strategies to launch their pipeline products by identifying potential geographies.
- Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
- Develop key strategic initiatives by studying the key strategies of top competitors.
- Develop market entry and market expansion strategies by identifying the geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce safer and more efficacious first-in-class molecules.
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 8
2 Global Antifungals Market to 2017 - Introduction 10
2.1 Overview 10
2.2 GBI Research Report Guidance 11
3 Global Antifungals Market to 2017 - Market Characterization 12
3.1 Introduction 12
3.2 Different Classes of Antifungals 12
3.3 Forecast for Global Antifungals Market 14
3.3.1 Revenues 14
3.3.2 Branded and Generic Market Share 15
3.3.3 Annual Cost of Treatment (ACT) 16
3.3.4 Treatment Usage Patterns 17
3.4 Drivers for the Antifungals Market 23
3.4.1 Large Patient Population 23
3.4.2 Increase in Diagnosis Rate 23
3.5 Barriers for the Antifungals Market 23
3.5.1 Prominence of Generics in the Market 23
3.5.2 High Unmet Need in Case of Serious Invasive Fungal Infections 23
4 Global Antifungals Market - Geographical Landscape 24
4.1 Revenue Analysis by Geography 24
4.2 The US 24
4.2.1 Revenue 24
4.2.2 Annual Cost of Treatment 26
4.2.3 Treatment Usage Pattern 27
4.3 Top Five Countries of Europe 33
4.3.1 Revenue 33
4.3.2 Annual Cost of Treatment 35
4.3.3 Treatment Usage Pattern 36
4.4 Japan 42
4.4.1 Revenue 42
4.4.2 Annual Cost of Treatment 43
4.4.3 Treatment Usage Pattern 44
5 Global Antifungals Market - Aspergillosis Therapeutics Market 50
5.1 Introduction 50
5.2 Market Forecasts 50
5.3 Annual Cost of Treatment 52
5.4 Treatment Usage Patterns 55
5.4.1 Diseased Population 57
5.4.2 Treatment Seeking Population 58
5.4.3 Diagnosed Population 59
5.4.4 Prescription Population 60
5.5 Treatment Flow Algorithm 61
5.5.1 Allergic Bronchopulmonary Aspergillosis 61
5.5.2 Invasive Aspergillosis 62
5.6 Branded and Generic Market Share 63
5.7 Major Marketed Products 64
5.7.1 Voriconazole (vfend) 64
5.7.2 Amphotericin B (amphocin) 64
5.7.3 AmBisome (amphotericin B) liposome for injection 64
5.7.4 Itraconazole (sporanox) 65
5.7.5 Caspofungin (cancidas) 65
5.7.6 Posaconazole (noxafil) 65
6 Global Antifungals Market - Dermatophytosis Therapeutics Market 66
6.1 Introduction 66
6.2 Market Forecasts 66
6.3 Annual Cost of Treatment 68
6.3.1 Annual Cost of Treatment for Tinea Cruris 68
6.3.2 Annual Cost of Treatment for Tinea Unguium (Onychomycosis) 70
6.3.3 Annual Cost of Treatment for Tinea Pedis 72
6.3.4 Annual Cost of Treatment for Tinea Capitis 74
6.3.5 Annual Cost of Treatment for Tinea Corporis 76
6.4 Treatment Usage Patterns 78
6.4.1 Diseased Population 80
6.4.2 Treatment Seeking Population 81
6.4.3 Diagnosed Population 82
6.4.4 Prescription Population 83
6.5 Treatment Flow Algorithm for Dermatophytosis 84
6.6 Branded and Generic Market Share 85
6.7 Major Marketed Products 86
6.7.1 Ketoconazole 2% cream (nizoral) 86
6.7.2 Clotrimazole 1% cream or lotion (lotrimin) 86
6.7.3 Econazole 1% cream or lotion (spectazole) 86
6.7.4 Miconazole 2% cream (monistat) 86
6.7.5 Terbinafine (lamisil) 87
6.7.6 Naftifine 1% cream (naftifin) 87
6.7.7 Griseofulvin 87
6.7.8 traconazole (sporanox) 87
6.7.9 Fluconazole (diflucan) 88
6.7.10 Sertaconazole nitrate cream (ertaczo) 88
7 Global Antifungals Market - Candidiasis Therapeutics Market 89
7.1 Introduction 89
7.2 Market Forecasts 89
7.3 Annual Cost of Treatment 91
7.3.1 Annual Cost of Treatment for Vaginal Candidiasis 91
7.3.2 Annual Cost of Treatment for Cutaneous Candidiasis 93
7.3.3 Annual Cost of Treatment for Oropharyngeal Candidiasis 94
7.3.4 Annual Cost of Treatment for Esophageal Candidiasis 95
7.3.5 Annual Cost of Treatment for Invasive Candidiasis 96
7.4 Treatment Usage Patterns 97
7.4.1 Diseased Population 99
7.4.2 Treatment Seeking Population 100
7.4.3 Diagnosed Population 101
7.4.4 Prescription Population 102
7.5 Treatment Flow Algorithm for Candidiasis 103
7.6 Branded and Generic Market Share 104
7.7 Major Marketed Products 105
7.7.1 Fluconazole 105
7.7.2 Itraconazole Oral Solution 105
7.7.3 Clotrimazole 105
7.7.4 Canestan 105
7.7.5 Anidulafungin (eraxis) 106
7.7.6 Nystatin Oral Suspension 106
7.7.7 Daktarin IV Solution 106
8 Global Antifungals Market - Pipeline Analysis 107
8.1 Introduction 107
8.2 Aspergillosis: Research and Development Pipeline 108
8.2.1 Overview 108
8.2.2 Phase lll 108
8.2.3 Phase ll 108
8.2.4 Phase l 108
8.2.5 Preclinical 108
8.2.6 Discovery 109
8.3 Dermatophytosis: Research and Development Pipeline 109
8.3.1 Overview 109
8.3.2 Phase lll 109
8.3.3 Phase ll 109
8.3.4 Phase l 110
8.3.5 Preclinical 110
8.4 Candidiasis: Research and Development Pipeline 110
8.4.1 Overview 110
8.4.2 Phase lll 110
8.4.3 Phase ll 110
8.4.4 Phase l 111
8.4.5 Preclinical 111
8.5 Profiles of Promising Drugs in the Antifungals Market 111
8.5.1 Eraxis + Vfend 111
8.5.2 Isavuconazole 112
8.5.3 NAFT-500 112
8.5.4 Fluconazole 113
9 Global Antifungals Market - Competitive Landscape 114
9.1 Company Profiles 114
9.1.1 Ferrer Internacional S.A. 114
9.1.2 BioDelivery Sciences International, Inc. 115
9.1.3 Pfizer Inc. 116
9.1.4 Merck & Co Inc 117
9.1.5 Astellas Pharma Inc 118
10 Global Antifungals Market - Strategic Consolidations 120
10.1 Mergers and Acquisitions 120
10.1.1 Overview 120
10.1.2 Major Mergers and Acquisitions Deals 120
10.1.3 M&A by Year 120
10.1.4 M&A by Deal Value 121
10.1.5 M&A by Geography 121
10.2 Co-Development Deals 122
10.2.1 Overview 122
10.2.2 Major Co-Development Deals 122
10.3 Licensing Deals 122
10.3.1 Overview 122
10.3.2 Major Licensing Deals 122
10.3.3 Licensing Deals by Year 123
11 Global Antifungals Market - Appendix 126
11.1 Market Definitions 126
11.2 Abbreviations 126
11.3 Research Methodology 127
11.3.1 Coverage 127
11.3.2 Secondary Research 128
11.3.3 Primary Research 128
11.4 Therapeutic Landscape 129
11.4.2 Market Size by Geography 131
11.5 Geographical Landscape 131
11.6 Pipeline Analysis 132
11.7 Competitive Landscape 132
11.7.1 Expert Panel Validation 132
11.8 Contact Us 132
11.9 Disclaimer 132
11.10 Sources 133
1.1 List of Tables
Table 1: Antifungals Market to 2017, Different Classes of Antifungals, 2011 12
Table 2: Antifungals Market to 2017, Global, Revenues ($bn), 2002-2010 14
Table 3: Antifungals Market to 2017, Global, Revenues ($bn), 2010-2017 14
Table 4: Antifungals Market to 2017, Global, Annual Cost of Treatment ($), 2002-2010 16
Table 5: Antifungals Market to 2017, Global, Annual Cost of Treatment ($), 2010-2017 16
Table 6: Antifungals Market to 2017, Global, Treatment Usage Patterns, (million), 2002-2010 17
Table 7: Antifungals Market to 2017, Global, Treatment Usage Patterns, (million), 2010-2017 18
Table 8: Antifungals Market to 2017, The US, Revenues ($bn), 2002-2010 25
Table 9: Antifungals Market to 2017, The US, Revenues ($bn), 2010-2017 25
Table 10: Antifungals Market to 2017, The US, Annual Cost of Treatment ($), 2002-2010 26
Table 11: Antifungals Market to 2017, The US, Annual Cost of Treatment ($), 2010-2017 26
Table 12: Antifungals Market to 2017, The US, Treatment Usage Patterns (million), 2002-2010 27
Table 13: Antifungals Market to 2017, The US, Treatment Usage Patterns (million), 2010-2017 28
Table 14: Antifungals Market to 2017, Top Five Countries of Europe, Revenues ($m), 2002-2010 33
Table 15: Antifungals Market to 2017, Top Five Countries of Europe, Revenues ($m), 2010-2017 34
Table 16: Antifungals Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 35
Table 17: Antifungals Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 35
Table 18: Antifungals Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns (million), 2002-2010 36
Table 19: Antifungals Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns (million), 2010-2017 37
Table 20: Antifungals Market to 2017, Japan, Revenues ($m), 2002-2010 42
Table 21: Antifungals Market to 2017, Japan, Revenues ($m), 2010-2017 42
Table 22: Antifungals Market to 2017, Japan, Annual Cost of Treatment ($), 2002-2010 43
Table 23: Antifungals Market to 2017, Japan, Annual Cost of Treatment ($), 2010-2017 43
Table 24: Antifungals Market to 2017, Japan, Treatment Usage Patterns, (million), 2002-2010 44
Table 25: Antifungals Market to 2017, Japan, Treatment Usage Patterns, (million), 2010-2017 45
Table 26: Aspergillosis Therapeutics Market, Global, Revenues ($m), 2002-2010 50
Table 27: Aspergillosis Therapeutics Market, Global, Revenues ($m), 2010 – 2017 50
Table 28: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Allergic Bronchopulmonary Aspergillosis ($), 2002-2010 52
Table 29: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Allergic Bronchopulmonary Aspergillosis ($), 2010-2017 52
Table 30: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Aspergillosis ($), 2002-2010 53
Table 31: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Aspergillosis ($), 2010-2017 53
Table 32: Aspergillosis Therapeutics Market, Global, Factors Influencing Life Threatening Infection, Invasive Aspergillosis, 2011 54
Table 33: Aspergillosis Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010 55
Table 34: Aspergillosis Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017 56
Table 35: Dermatophytosis Therapeutics Market, Global, Revenues ($bn), 2002-2010 66
Table 36: Dermatophytosis Therapeutics Market, Global, Revenues ($bn), 2010-2017 67
Table 37: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Cruris ($), 2002-2010 68
Table 38: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Cruris ($), 2010-2017 68
Table 39: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Unguium ($), 2002-2010 70
Table 40: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Unguium ($), 2010-2017 70
Table 41: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Pedis ($), 2002-2010 72
Table 42: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Pedis ($), 2010-2017 72
Table 43: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Capitis ($), 2002-2010 74
Table 44: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Capitis ($), 2010-2017 74
Table 45: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Corporis ($), 2002-2010 76
Table 46: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Corporis ($), 2010-2017 76
Table 47: Dermatophytosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2010 78
Table 48: Dermatophytosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010-2017 79
Table 49: Candidiasis Therapeutics Market, Global, Revenues ($bn), 2002-2010 89
Table 50: Candidiasis Therapeutics Market, Global, Revenues ($bn), 2010-2017 90
Table 51: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Vaginal Candidiasis ($), 2002-2010 91
Table 52: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Vaginal Candidiasis ($), 2010-2017 91
Table 53: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Cutaneous Candidiasis ($), 2002-2010 93
Table 54: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Cutaneous Candidiasis ($), 2010-2017 93
Table 55: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Oropharyngeal Candidiasis ($), 2002-2010 94
Table 56: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Oropharyngeal Candidiasis ($), 2010-2017 94
Table 57: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Esophageal Candidiasis ($), 2002-2010 95
Table 58: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Esophageal Candidiasis ($), 2010-2017 95
Table 59: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Candidiasis ($), 2002-2010 96
Table 60: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Candidiasis ($), 2010-2017 96
Table 61: Candidiasis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010 97
Table 62: Candidiasis Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017 98
Table 63: Aspergillosis Therapeutics Market, Global, Phase lll, 2011 108
Table 64: Aspergillosis Therapeutics Market, Global, Phase ll, 2011 108
Table 65: Aspergillosis Therapeutics Market, Global, Phase l, 2011 108
Table 66: Aspergillosis Therapeutics Market, Global, Preclinical, 2011 108
Table 67: Aspergillosis Therapeutics Market, Global, Discovery, 2011 109
Table 68: Dermatophytosis Therapeutics Market, Global, Phase lll, 2011 109
Table 69: Dermatophytosis Therapeutics Market, Global, Phase ll, 2011 109
Table 70: Dermatophytosis Therapeutics Market, Global, Phase l, 2011 110
Table 71: Dermatophytosis Therapeutics Market, Global, Preclinical, 2011 110
Table 72: Candidiasis Therapeutics Market, Global, Phase lll, 2011 110
Table 73: Candidiasis Therapeutics Market, Global, Phase ll, 2011 110
Table 74: Candidiasis Therapeutics Market, Global, Phase l, 2011 111
Table 75: Candidiasis Therapeutics Market, Global, Preclinical, 2011 111
1.2 List of Figures
Figure 1: Antifungals Market to 2017, Global, Revenues ($bn), 2002-2017 14
Figure 2: Antifungals Market to 2017, Global, Branded and Generic Market Share (%), 2010-2017 15
Figure 3: Antifungals Market to 2017, Global, Annual Cost of Treatment ($), 2002-2017 16
Figure 4: Antifungals Market to 2017, Global, Treatment Usage Patterns, (million), 2002-2017 17
Figure 5: Antifungals Market to 2017, Global, Diseased Population (million), 2002-2017 19
Figure 6: Antifungals Market to 2017, Global, Treatment Seeking Population (million), 2002-2017 20
Figure 7: Antifungals Market to 2017, Global, Diagnosed Population (million), 2002-2017 21
Figure 8: Antifungals Market to 2017, Global, Prescription Population (million), 2002-2017 22
Figure 9: Antifungals Market to 2017, The US, Revenues ($bn), 2002-2017 24
Figure 10: Antifungals Market to 2017, The US, Annual Cost of Treatment ($), 2002-2017 26
Figure 11: Antifungals Market to 2017, The US, Treatment Usage Patterns (million), 2002-2017 27
Figure 12: Antifungals Market to 2017, The US, Diseased Population (million), 2002-2017 29
Figure 13: Antifungals Market to 2017, The US, Treatment Seeking Population (million), 2002-2017 30
Figure 14: Antifungals Market to 2017, The US, Diagnosed Population (million), 2002-2017 31
Figure 15: Antifungals Market to 2017, The US, Prescription Population (million), 2002-2017 32
Figure 16: Antifungals Market to 2017, Top Five Countries of Europe, Revenues ($bn), 2002-2017 33
Figure 17: Antifungals Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 35
Figure 18: Antifungals Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns (million), 2002-2017 36
Figure 19: Antifungals Market to 2017, Top Five Countries of Europe, Diseased Population (million), 2002-2017 38
Figure 20: Antifungals Market to 2017, Top Five Countries of Europe, Treatment Seeking Population (million), 2002-2017 39
Figure 21: Antifungals Market to 2017, Top Five Countries of Europe, Diagnosed Population (million), 2002-2017 40
Figure 22: Antifungals Market to 2017, Top Five Countries of Europe, Prescription Population (million), 2002-2017 41
Figure 23: Antifungals Market to 2017, Japan, Revenues ($m), 2002-2017 42
Figure 24: Antifungals Market to 2017, Japan, Annual Cost of Treatment ($), 2002-2017 43
Figure 25: Antifungals Market to 2017, Japan, Treatment Usage Patterns, (million), 2002-2017 44
Figure 26: Antifungals Market to 2017, Japan, Diseased Population (million), 2002-2017 46
Figure 27: Antifungals Market to 2017, Japan, Treatment Seeking Population (million), 2002-2017 47
Figure 28: Antifungals Market to 2017, Japan, Diagnosed Population (million), 2002-2017 48
Figure 29: Antifungals Market to 2017, Japan, Prescription Population (million), 2002-2017 49
Figure 30: Aspergillosis Therapeutics Market, Global, Revenues ($m), 2002-2017 50
Figure 31: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Allergic Bronchopulmonary Aspergillosis ($), 2002-2017 52
Figure 32: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Aspergillosis ($), 2002-2017 53
Figure 33: Aspergillosis Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017 55
Figure 34: Aspergillosis Therapeutics Market, Global, Diseased Population (million), 2002-2017 57
Figure 35: Aspergillosis Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 58
Figure 36: Aspergillosis Therapeutics Market, Global, Diagnosed Population (million), 2002-2017 59
Figure 37: Aspergillosis Therapeutics Market, Global, Prescription Population (million), 2002-2017 60
Figure 38: Aspergillosis Therapeutics Market, Global, Treatment Flow Algorithm for Allergic Bronchopulmonary Aspergillosis, 2011 61
Figure 39: Aspergillosis Therapeutics Market, Global, Treatment Flow Algorithm for Invasive Aspergillosis, 2011 62
Figure 40: Aspergillosis Therapeutics Market, Global, Branded and Generic Market Share (%), 2010-2017 63
Figure 41: Dermatophytosis Therapeutics Market, Global, Revenues ($bn), 2002-2017 66
Figure 42: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Cruris ($), 2002-2017 68
Figure 43: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Unguium ($), 2002-2017 70
Figure 44: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Pedis ($), 2002-2017 72
Figure 45: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Capitis ($), 2002-2017 74
Figure 46: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Corporis ($), 2002-2017 76
Figure 47: Dermatophytosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2017 78
Figure 48: Dermatophytosis Therapeutics Market, Global, Diseased Population (million), 2002-2017 80
Figure 49: Dermatophytosis Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 81
Figure 50: Dermatophytosis Therapeutics Market, Global, Diagnosed Population (million), 2002-2017 82
Figure 51: Dermatophytosis Therapeutics Market, Global, Prescription Population (million), 2002-2017 83
Figure 52: Dermatophytosis Therapeutics Market, Global, Treatment Flow Algorithm, 2011 84
Figure 53: Dermatophytosis Therapeutics Market, Global, Branded and Generic Market Share (%), 2010-2017 85
Figure 54: Candidiasis Therapeutics Market, Global, Revenues ($bn), 2002-2017 89
Figure 55: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Vaginal Candidiasis ($), 2002-2017 91
Figure 56: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Cutaneous Candidiasis ($), 2002-2017 93
Figure 57: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Oropharyngeal Candidiasis ($), 2002-2017 94
Figure 58: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Esophageal Candidiasis ($), 2002-2017 95
Figure 59: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Candidiasis ($), 2002-2017 96
Figure 60: Candidiasis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017 97
Figure 61: Candidiasis Therapeutics Market, Global, Diseased Population (million), 2002-2017 99
Figure 62: Candidiasis Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 100
Figure 63: Candidiasis Therapeutics Market, Global, Diagnosed Population (million), 2002-2017 101
Figure 64: Candidiasis Therapeutics Market, Global, Prescription Population (million), 2002-2017 102
Figure 65: Candidiasis Therapeutics Market, Global, Treatment Flow Algorithm, 2011 103
Figure 66: Candidiasis Therapeutics Market, Global, Branded and Generic Market Share (%), 2010-2017 104
Figure 67: Antifungals Market to 2017 to 2017, Global, Pipeline Analysis, 2011 107
Figure 68: Antifungals Market to 2017, SWOT Analysis - Ferrer Internacional SA 114
Figure 69: Antifungals Market to 2017, SWOT Analysis - BioDelivery Sciences International Inc 116
Figure 70: Antifungals Market to 2017, SWOT Analysis - Pfizer Inc 117
Figure 71: Antifungals Market to 2017, SWOT Analysis – Merck & Co Inc 118
Figure 72: Antifungals Market to 2017, SWOT Analysis – Astellas Pharma Inc 119
Figure 73: Antifungals Therapeutics Market, Global, M&A by Year, 2009-2011 120
Figure 74: Antifungals Therapeutics Market, Global, M&A by Deal Value, 2009-2011 121
Figure 75: Antifungals Therapeutics Market, Global, M&A by Geography, 2009 -2011 121
Figure 76: Antifungals Therapeutics Market, Global, Licensing Deals by Year, 2009-2011 123
Figure 77: Antifungals Therapeutics Market, Global, Licensing Deals by Deal Value, 2009-2011 124
Figure 78: Antifungals Therapeutics Market, Global, Licensing Deals by Geography, 2009-2011 125
Figure 79: GBI Research Market Forecasting Model 131
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 8
2 Global Antifungals Market to 2017 - Introduction 10
2.1 Overview 10
2.2 GBI Research Report Guidance 11
3 Global Antifungals Market to 2017 - Market Characterization 12
3.1 Introduction 12
3.2 Different Classes of Antifungals 12
3.3 Forecast for Global Antifungals Market 14
3.3.1 Revenues 14
3.3.2 Branded and Generic Market Share 15
3.3.3 Annual Cost of Treatment (ACT) 16
3.3.4 Treatment Usage Patterns 17
3.4 Drivers for the Antifungals Market 23
3.4.1 Large Patient Population 23
3.4.2 Increase in Diagnosis Rate 23
3.5 Barriers for the Antifungals Market 23
3.5.1 Prominence of Generics in the Market 23
3.5.2 High Unmet Need in Case of Serious Invasive Fungal Infections 23
4 Global Antifungals Market - Geographical Landscape 24
4.1 Revenue Analysis by Geography 24
4.2 The US 24
4.2.1 Revenue 24
4.2.2 Annual Cost of Treatment 26
4.2.3 Treatment Usage Pattern 27
4.3 Top Five Countries of Europe 33
4.3.1 Revenue 33
4.3.2 Annual Cost of Treatment 35
4.3.3 Treatment Usage Pattern 36
4.4 Japan 42
4.4.1 Revenue 42
4.4.2 Annual Cost of Treatment 43
4.4.3 Treatment Usage Pattern 44
5 Global Antifungals Market - Aspergillosis Therapeutics Market 50
5.1 Introduction 50
5.2 Market Forecasts 50
5.3 Annual Cost of Treatment 52
5.4 Treatment Usage Patterns 55
5.4.1 Diseased Population 57
5.4.2 Treatment Seeking Population 58
5.4.3 Diagnosed Population 59
5.4.4 Prescription Population 60
5.5 Treatment Flow Algorithm 61
5.5.1 Allergic Bronchopulmonary Aspergillosis 61
5.5.2 Invasive Aspergillosis 62
5.6 Branded and Generic Market Share 63
5.7 Major Marketed Products 64
5.7.1 Voriconazole (vfend) 64
5.7.2 Amphotericin B (amphocin) 64
5.7.3 AmBisome (amphotericin B) liposome for injection 64
5.7.4 Itraconazole (sporanox) 65
5.7.5 Caspofungin (cancidas) 65
5.7.6 Posaconazole (noxafil) 65
6 Global Antifungals Market - Dermatophytosis Therapeutics Market 66
6.1 Introduction 66
6.2 Market Forecasts 66
6.3 Annual Cost of Treatment 68
6.3.1 Annual Cost of Treatment for Tinea Cruris 68
6.3.2 Annual Cost of Treatment for Tinea Unguium (Onychomycosis) 70
6.3.3 Annual Cost of Treatment for Tinea Pedis 72
6.3.4 Annual Cost of Treatment for Tinea Capitis 74
6.3.5 Annual Cost of Treatment for Tinea Corporis 76
6.4 Treatment Usage Patterns 78
6.4.1 Diseased Population 80
6.4.2 Treatment Seeking Population 81
6.4.3 Diagnosed Population 82
6.4.4 Prescription Population 83
6.5 Treatment Flow Algorithm for Dermatophytosis 84
6.6 Branded and Generic Market Share 85
6.7 Major Marketed Products 86
6.7.1 Ketoconazole 2% cream (nizoral) 86
6.7.2 Clotrimazole 1% cream or lotion (lotrimin) 86
6.7.3 Econazole 1% cream or lotion (spectazole) 86
6.7.4 Miconazole 2% cream (monistat) 86
6.7.5 Terbinafine (lamisil) 87
6.7.6 Naftifine 1% cream (naftifin) 87
6.7.7 Griseofulvin 87
6.7.8 traconazole (sporanox) 87
6.7.9 Fluconazole (diflucan) 88
6.7.10 Sertaconazole nitrate cream (ertaczo) 88
7 Global Antifungals Market - Candidiasis Therapeutics Market 89
7.1 Introduction 89
7.2 Market Forecasts 89
7.3 Annual Cost of Treatment 91
7.3.1 Annual Cost of Treatment for Vaginal Candidiasis 91
7.3.2 Annual Cost of Treatment for Cutaneous Candidiasis 93
7.3.3 Annual Cost of Treatment for Oropharyngeal Candidiasis 94
7.3.4 Annual Cost of Treatment for Esophageal Candidiasis 95
7.3.5 Annual Cost of Treatment for Invasive Candidiasis 96
7.4 Treatment Usage Patterns 97
7.4.1 Diseased Population 99
7.4.2 Treatment Seeking Population 100
7.4.3 Diagnosed Population 101
7.4.4 Prescription Population 102
7.5 Treatment Flow Algorithm for Candidiasis 103
7.6 Branded and Generic Market Share 104
7.7 Major Marketed Products 105
7.7.1 Fluconazole 105
7.7.2 Itraconazole Oral Solution 105
7.7.3 Clotrimazole 105
7.7.4 Canestan 105
7.7.5 Anidulafungin (eraxis) 106
7.7.6 Nystatin Oral Suspension 106
7.7.7 Daktarin IV Solution 106
8 Global Antifungals Market - Pipeline Analysis 107
8.1 Introduction 107
8.2 Aspergillosis: Research and Development Pipeline 108
8.2.1 Overview 108
8.2.2 Phase lll 108
8.2.3 Phase ll 108
8.2.4 Phase l 108
8.2.5 Preclinical 108
8.2.6 Discovery 109
8.3 Dermatophytosis: Research and Development Pipeline 109
8.3.1 Overview 109
8.3.2 Phase lll 109
8.3.3 Phase ll 109
8.3.4 Phase l 110
8.3.5 Preclinical 110
8.4 Candidiasis: Research and Development Pipeline 110
8.4.1 Overview 110
8.4.2 Phase lll 110
8.4.3 Phase ll 110
8.4.4 Phase l 111
8.4.5 Preclinical 111
8.5 Profiles of Promising Drugs in the Antifungals Market 111
8.5.1 Eraxis + Vfend 111
8.5.2 Isavuconazole 112
8.5.3 NAFT-500 112
8.5.4 Fluconazole 113
9 Global Antifungals Market - Competitive Landscape 114
9.1 Company Profiles 114
9.1.1 Ferrer Internacional S.A. 114
9.1.2 BioDelivery Sciences International, Inc. 115
9.1.3 Pfizer Inc. 116
9.1.4 Merck & Co Inc 117
9.1.5 Astellas Pharma Inc 118
10 Global Antifungals Market - Strategic Consolidations 120
10.1 Mergers and Acquisitions 120
10.1.1 Overview 120
10.1.2 Major Mergers and Acquisitions Deals 120
10.1.3 M&A by Year 120
10.1.4 M&A by Deal Value 121
10.1.5 M&A by Geography 121
10.2 Co-Development Deals 122
10.2.1 Overview 122
10.2.2 Major Co-Development Deals 122
10.3 Licensing Deals 122
10.3.1 Overview 122
10.3.2 Major Licensing Deals 122
10.3.3 Licensing Deals by Year 123
11 Global Antifungals Market - Appendix 126
11.1 Market Definitions 126
11.2 Abbreviations 126
11.3 Research Methodology 127
11.3.1 Coverage 127
11.3.2 Secondary Research 128
11.3.3 Primary Research 128
11.4 Therapeutic Landscape 129
11.4.2 Market Size by Geography 131
11.5 Geographical Landscape 131
11.6 Pipeline Analysis 132
11.7 Competitive Landscape 132
11.7.1 Expert Panel Validation 132
11.8 Contact Us 132
11.9 Disclaimer 132
11.10 Sources 133
1.1 List of Tables
Table 1: Antifungals Market to 2017, Different Classes of Antifungals, 2011 12
Table 2: Antifungals Market to 2017, Global, Revenues ($bn), 2002-2010 14
Table 3: Antifungals Market to 2017, Global, Revenues ($bn), 2010-2017 14
Table 4: Antifungals Market to 2017, Global, Annual Cost of Treatment ($), 2002-2010 16
Table 5: Antifungals Market to 2017, Global, Annual Cost of Treatment ($), 2010-2017 16
Table 6: Antifungals Market to 2017, Global, Treatment Usage Patterns, (million), 2002-2010 17
Table 7: Antifungals Market to 2017, Global, Treatment Usage Patterns, (million), 2010-2017 18
Table 8: Antifungals Market to 2017, The US, Revenues ($bn), 2002-2010 25
Table 9: Antifungals Market to 2017, The US, Revenues ($bn), 2010-2017 25
Table 10: Antifungals Market to 2017, The US, Annual Cost of Treatment ($), 2002-2010 26
Table 11: Antifungals Market to 2017, The US, Annual Cost of Treatment ($), 2010-2017 26
Table 12: Antifungals Market to 2017, The US, Treatment Usage Patterns (million), 2002-2010 27
Table 13: Antifungals Market to 2017, The US, Treatment Usage Patterns (million), 2010-2017 28
Table 14: Antifungals Market to 2017, Top Five Countries of Europe, Revenues ($m), 2002-2010 33
Table 15: Antifungals Market to 2017, Top Five Countries of Europe, Revenues ($m), 2010-2017 34
Table 16: Antifungals Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 35
Table 17: Antifungals Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 35
Table 18: Antifungals Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns (million), 2002-2010 36
Table 19: Antifungals Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns (million), 2010-2017 37
Table 20: Antifungals Market to 2017, Japan, Revenues ($m), 2002-2010 42
Table 21: Antifungals Market to 2017, Japan, Revenues ($m), 2010-2017 42
Table 22: Antifungals Market to 2017, Japan, Annual Cost of Treatment ($), 2002-2010 43
Table 23: Antifungals Market to 2017, Japan, Annual Cost of Treatment ($), 2010-2017 43
Table 24: Antifungals Market to 2017, Japan, Treatment Usage Patterns, (million), 2002-2010 44
Table 25: Antifungals Market to 2017, Japan, Treatment Usage Patterns, (million), 2010-2017 45
Table 26: Aspergillosis Therapeutics Market, Global, Revenues ($m), 2002-2010 50
Table 27: Aspergillosis Therapeutics Market, Global, Revenues ($m), 2010 – 2017 50
Table 28: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Allergic Bronchopulmonary Aspergillosis ($), 2002-2010 52
Table 29: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Allergic Bronchopulmonary Aspergillosis ($), 2010-2017 52
Table 30: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Aspergillosis ($), 2002-2010 53
Table 31: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Aspergillosis ($), 2010-2017 53
Table 32: Aspergillosis Therapeutics Market, Global, Factors Influencing Life Threatening Infection, Invasive Aspergillosis, 2011 54
Table 33: Aspergillosis Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2010 55
Table 34: Aspergillosis Therapeutics Market, Global, Treatment Usage Pattern (million), 2010-2017 56
Table 35: Dermatophytosis Therapeutics Market, Global, Revenues ($bn), 2002-2010 66
Table 36: Dermatophytosis Therapeutics Market, Global, Revenues ($bn), 2010-2017 67
Table 37: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Cruris ($), 2002-2010 68
Table 38: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Cruris ($), 2010-2017 68
Table 39: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Unguium ($), 2002-2010 70
Table 40: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Unguium ($), 2010-2017 70
Table 41: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Pedis ($), 2002-2010 72
Table 42: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Pedis ($), 2010-2017 72
Table 43: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Capitis ($), 2002-2010 74
Table 44: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Capitis ($), 2010-2017 74
Table 45: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Corporis ($), 2002-2010 76
Table 46: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Corporis ($), 2010-2017 76
Table 47: Dermatophytosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2010 78
Table 48: Dermatophytosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2010-2017 79
Table 49: Candidiasis Therapeutics Market, Global, Revenues ($bn), 2002-2010 89
Table 50: Candidiasis Therapeutics Market, Global, Revenues ($bn), 2010-2017 90
Table 51: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Vaginal Candidiasis ($), 2002-2010 91
Table 52: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Vaginal Candidiasis ($), 2010-2017 91
Table 53: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Cutaneous Candidiasis ($), 2002-2010 93
Table 54: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Cutaneous Candidiasis ($), 2010-2017 93
Table 55: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Oropharyngeal Candidiasis ($), 2002-2010 94
Table 56: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Oropharyngeal Candidiasis ($), 2010-2017 94
Table 57: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Esophageal Candidiasis ($), 2002-2010 95
Table 58: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Esophageal Candidiasis ($), 2010-2017 95
Table 59: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Candidiasis ($), 2002-2010 96
Table 60: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Candidiasis ($), 2010-2017 96
Table 61: Candidiasis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2010 97
Table 62: Candidiasis Therapeutics Market, Global, Treatment Usage Patterns (million), 2010-2017 98
Table 63: Aspergillosis Therapeutics Market, Global, Phase lll, 2011 108
Table 64: Aspergillosis Therapeutics Market, Global, Phase ll, 2011 108
Table 65: Aspergillosis Therapeutics Market, Global, Phase l, 2011 108
Table 66: Aspergillosis Therapeutics Market, Global, Preclinical, 2011 108
Table 67: Aspergillosis Therapeutics Market, Global, Discovery, 2011 109
Table 68: Dermatophytosis Therapeutics Market, Global, Phase lll, 2011 109
Table 69: Dermatophytosis Therapeutics Market, Global, Phase ll, 2011 109
Table 70: Dermatophytosis Therapeutics Market, Global, Phase l, 2011 110
Table 71: Dermatophytosis Therapeutics Market, Global, Preclinical, 2011 110
Table 72: Candidiasis Therapeutics Market, Global, Phase lll, 2011 110
Table 73: Candidiasis Therapeutics Market, Global, Phase ll, 2011 110
Table 74: Candidiasis Therapeutics Market, Global, Phase l, 2011 111
Table 75: Candidiasis Therapeutics Market, Global, Preclinical, 2011 111
1.2 List of Figures
Figure 1: Antifungals Market to 2017, Global, Revenues ($bn), 2002-2017 14
Figure 2: Antifungals Market to 2017, Global, Branded and Generic Market Share (%), 2010-2017 15
Figure 3: Antifungals Market to 2017, Global, Annual Cost of Treatment ($), 2002-2017 16
Figure 4: Antifungals Market to 2017, Global, Treatment Usage Patterns, (million), 2002-2017 17
Figure 5: Antifungals Market to 2017, Global, Diseased Population (million), 2002-2017 19
Figure 6: Antifungals Market to 2017, Global, Treatment Seeking Population (million), 2002-2017 20
Figure 7: Antifungals Market to 2017, Global, Diagnosed Population (million), 2002-2017 21
Figure 8: Antifungals Market to 2017, Global, Prescription Population (million), 2002-2017 22
Figure 9: Antifungals Market to 2017, The US, Revenues ($bn), 2002-2017 24
Figure 10: Antifungals Market to 2017, The US, Annual Cost of Treatment ($), 2002-2017 26
Figure 11: Antifungals Market to 2017, The US, Treatment Usage Patterns (million), 2002-2017 27
Figure 12: Antifungals Market to 2017, The US, Diseased Population (million), 2002-2017 29
Figure 13: Antifungals Market to 2017, The US, Treatment Seeking Population (million), 2002-2017 30
Figure 14: Antifungals Market to 2017, The US, Diagnosed Population (million), 2002-2017 31
Figure 15: Antifungals Market to 2017, The US, Prescription Population (million), 2002-2017 32
Figure 16: Antifungals Market to 2017, Top Five Countries of Europe, Revenues ($bn), 2002-2017 33
Figure 17: Antifungals Market to 2017, Top Five Countries of Europe, Annual Cost of Treatment ($), 2002-2017 35
Figure 18: Antifungals Market to 2017, Top Five Countries of Europe, Treatment Usage Patterns (million), 2002-2017 36
Figure 19: Antifungals Market to 2017, Top Five Countries of Europe, Diseased Population (million), 2002-2017 38
Figure 20: Antifungals Market to 2017, Top Five Countries of Europe, Treatment Seeking Population (million), 2002-2017 39
Figure 21: Antifungals Market to 2017, Top Five Countries of Europe, Diagnosed Population (million), 2002-2017 40
Figure 22: Antifungals Market to 2017, Top Five Countries of Europe, Prescription Population (million), 2002-2017 41
Figure 23: Antifungals Market to 2017, Japan, Revenues ($m), 2002-2017 42
Figure 24: Antifungals Market to 2017, Japan, Annual Cost of Treatment ($), 2002-2017 43
Figure 25: Antifungals Market to 2017, Japan, Treatment Usage Patterns, (million), 2002-2017 44
Figure 26: Antifungals Market to 2017, Japan, Diseased Population (million), 2002-2017 46
Figure 27: Antifungals Market to 2017, Japan, Treatment Seeking Population (million), 2002-2017 47
Figure 28: Antifungals Market to 2017, Japan, Diagnosed Population (million), 2002-2017 48
Figure 29: Antifungals Market to 2017, Japan, Prescription Population (million), 2002-2017 49
Figure 30: Aspergillosis Therapeutics Market, Global, Revenues ($m), 2002-2017 50
Figure 31: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Allergic Bronchopulmonary Aspergillosis ($), 2002-2017 52
Figure 32: Aspergillosis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Aspergillosis ($), 2002-2017 53
Figure 33: Aspergillosis Therapeutics Market, Global, Treatment Usage Pattern (million), 2002-2017 55
Figure 34: Aspergillosis Therapeutics Market, Global, Diseased Population (million), 2002-2017 57
Figure 35: Aspergillosis Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 58
Figure 36: Aspergillosis Therapeutics Market, Global, Diagnosed Population (million), 2002-2017 59
Figure 37: Aspergillosis Therapeutics Market, Global, Prescription Population (million), 2002-2017 60
Figure 38: Aspergillosis Therapeutics Market, Global, Treatment Flow Algorithm for Allergic Bronchopulmonary Aspergillosis, 2011 61
Figure 39: Aspergillosis Therapeutics Market, Global, Treatment Flow Algorithm for Invasive Aspergillosis, 2011 62
Figure 40: Aspergillosis Therapeutics Market, Global, Branded and Generic Market Share (%), 2010-2017 63
Figure 41: Dermatophytosis Therapeutics Market, Global, Revenues ($bn), 2002-2017 66
Figure 42: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Cruris ($), 2002-2017 68
Figure 43: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Unguium ($), 2002-2017 70
Figure 44: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Pedis ($), 2002-2017 72
Figure 45: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Capitis ($), 2002-2017 74
Figure 46: Dermatophytosis Therapeutics Market, Global, Annual Cost of Treatment, Tinea Corporis ($), 2002-2017 76
Figure 47: Dermatophytosis Therapeutics Market, Global, Treatment Usage Patterns, (million), 2002-2017 78
Figure 48: Dermatophytosis Therapeutics Market, Global, Diseased Population (million), 2002-2017 80
Figure 49: Dermatophytosis Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 81
Figure 50: Dermatophytosis Therapeutics Market, Global, Diagnosed Population (million), 2002-2017 82
Figure 51: Dermatophytosis Therapeutics Market, Global, Prescription Population (million), 2002-2017 83
Figure 52: Dermatophytosis Therapeutics Market, Global, Treatment Flow Algorithm, 2011 84
Figure 53: Dermatophytosis Therapeutics Market, Global, Branded and Generic Market Share (%), 2010-2017 85
Figure 54: Candidiasis Therapeutics Market, Global, Revenues ($bn), 2002-2017 89
Figure 55: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Vaginal Candidiasis ($), 2002-2017 91
Figure 56: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Cutaneous Candidiasis ($), 2002-2017 93
Figure 57: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Oropharyngeal Candidiasis ($), 2002-2017 94
Figure 58: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Esophageal Candidiasis ($), 2002-2017 95
Figure 59: Candidiasis Therapeutics Market, Global, Annual Cost of Treatment, Invasive Candidiasis ($), 2002-2017 96
Figure 60: Candidiasis Therapeutics Market, Global, Treatment Usage Patterns (million), 2002-2017 97
Figure 61: Candidiasis Therapeutics Market, Global, Diseased Population (million), 2002-2017 99
Figure 62: Candidiasis Therapeutics Market, Global, Treatment Seeking Population (million), 2002-2017 100
Figure 63: Candidiasis Therapeutics Market, Global, Diagnosed Population (million), 2002-2017 101
Figure 64: Candidiasis Therapeutics Market, Global, Prescription Population (million), 2002-2017 102
Figure 65: Candidiasis Therapeutics Market, Global, Treatment Flow Algorithm, 2011 103
Figure 66: Candidiasis Therapeutics Market, Global, Branded and Generic Market Share (%), 2010-2017 104
Figure 67: Antifungals Market to 2017 to 2017, Global, Pipeline Analysis, 2011 107
Figure 68: Antifungals Market to 2017, SWOT Analysis - Ferrer Internacional SA 114
Figure 69: Antifungals Market to 2017, SWOT Analysis - BioDelivery Sciences International Inc 116
Figure 70: Antifungals Market to 2017, SWOT Analysis - Pfizer Inc 117
Figure 71: Antifungals Market to 2017, SWOT Analysis – Merck & Co Inc 118
Figure 72: Antifungals Market to 2017, SWOT Analysis – Astellas Pharma Inc 119
Figure 73: Antifungals Therapeutics Market, Global, M&A by Year, 2009-2011 120
Figure 74: Antifungals Therapeutics Market, Global, M&A by Deal Value, 2009-2011 121
Figure 75: Antifungals Therapeutics Market, Global, M&A by Geography, 2009 -2011 121
Figure 76: Antifungals Therapeutics Market, Global, Licensing Deals by Year, 2009-2011 123
Figure 77: Antifungals Therapeutics Market, Global, Licensing Deals by Deal Value, 2009-2011 124
Figure 78: Antifungals Therapeutics Market, Global, Licensing Deals by Geography, 2009-2011 125
Figure 79: GBI Research Market Forecasting Model 131
